NCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT07466901 2026-03-12
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Fudan University
Phase NA Not yet recruiting
NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
NCT03083041 2026-03-03
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT07432087 2026-02-25
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT05451290 2026-02-12
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07400094 2026-02-10
NeoCamre-HN
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Not yet recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT05524168 2026-01-15
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT04639180 2025-12-30
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting